Literature DB >> 10989970

Nuclear medicine imaging procedures in differentiated thyroid carcinoma patients with negative iodine scan.

D Rubello1, G Saladini, A Carpi, D Casara.   

Abstract

Radioiodine treatment following surgery is an effective therapy in differentiated thyroid carcinoma (DTC) patients. However, in DTC patients with metastases characterized by very low or absent iodine uptake, total thyroidectomy and radical loco-regional lymphoadenectomy is the only effective therapeutic approach. In the present article, we have discussed the most recently available nuclear medicine techniques utilized for the detection of DTC metastases that have lost the capacity to trap radioiodine. A review of the data published in the literature has been presented, and a comparative analysis made of the results obtained by other imaging modalities such as high resolution neck ultrasonography (US), computed tomography (CT) and magnetic resonance imaging (MRI). In our experience, the most sensitive and accurate imaging procedure is represented by the combination of neck US and whole body 99mTc-methoxy-isobutylisonitrile (99mTc-MIBI) scintigraphy; this combination might be proposed as a first-line diagnostic approach in DTC patients with increased serum thyroglobulin (Tg) levels and negative high dose 131I scans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10989970     DOI: 10.1016/S0753-3322(00)80060-8

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  4 in total

1.  Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value.

Authors:  Marcel P M Stokkel; Robbert B Verkooijen; Jan W A Smit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-26       Impact factor: 9.236

2.  Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management.

Authors:  Di Wu; Dorina Ylli; Cristiane J Gomes Lima; Wen Lee; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633

3.  Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.

Authors:  Marcel P M Stokkel; Henna I E Reigman; Robbert B T Verkooijen; Jan W Smit
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-15       Impact factor: 4.553

4.  Values of (99m)Tc-methoxyisobutylisonitrile imaging after first-time large-dose (131)I therapy in treating differentiated thyroid cancer.

Authors:  Xiaomei Pan; Dong Duan; Yuquan Zhu; Hua Pang; Lili Guan; Zhixiang Lv
Journal:  Onco Targets Ther       Date:  2016-02-10       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.